Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHLAMYDIA IN-OFFICE RAPID DIAGNOSTIC ASSAYS

This article was originally published in The Gray Sheet

Executive Summary

CHLAMYDIA IN-OFFICE RAPID DIAGNOSTIC ASSAYS lack sufficient sensitivity to ensure treatment of asymptomatic women with Chlamydia infections, Edward Book, MD, University of Alabama Department of Medicine, Birmingham, et al. conclude in a study published in the Sept. 21 Journal of the American Medical Association. Noting the 48.5% sensitivity rate seen with the rapid Chlamydia assay in the study, the authors point out that the rapid test, "had it been used exclusively for Chlamydia screening, would have resulted in treatment for less than half of all women with culture-proven infections."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel